Hemofilia a

Medicina (Buenos Aires) versión ISSN 0025-7680
Medicina (B. Aires) vol.70 no.3 Ciudad Autónoma de Buenos Aires mayo/jun. 2010 TERAPÉUTICA CLÍNICA
Secondary prophylaxis with rFVIIa in hemophilia and inhibitors: Recommendations from an Experts Committee from Argentina
Raúl Pérez Bianco1,2, Daniela Neme2, Miguel Candela1,2, Miguel de Tezanos Pinto1,2
1Instituto de Investigaciones Hematológicas Mariano R. Castex, Academia Nacional de Medicina, Buenos Aires;
2Fundación de la Hemofilia, Buenos Aires, Argentina
Postal address: Dr. Raúl Pérez Bianco, Instituto de Investigaciones Hematológicas Mariano R. Castex, Academia Nacional de Medicina, J.A. Pacheco de Melo 3081 PB, 1425, Buenos Aires, Argentina Fax: [phone] int: 29 e-mail: [e-mail]
Abstract
Secondary prophylaxis with rFVIIa has been the subject of several publications in the past few years. However, there is no general consensus on how this treatment should be put into practice, as publications have been very heterogeneous in the dosing schedule they report. Furthermore, the mechanism of action of rFVIIa and its short half life have been used as arguments against its role in prophylaxis. There have been a series of recent publications that show that rFVIIa can traffic through the intact endothelium and be stored in the subendothelium of several organs for a prolonged period of time. In order to consensuate the role of rFVIIa in prophylaxis, a group of experts from Argentina, resumed available information regarding pharmacology and clinical experience with this treatment, and developed a series of recommendations to use this drug in the prophylaxis setting.
Key words: rFVIIa; Prophylaxis; Hemophilia; Inhibitors
Resumen
Profilaxis secundaria con rFVIIa en pacientes con hemofilia e inhibidores: Recomendaciones de un comité de expertos de Argentina. La profilaxis secundaria con factor VII activado recombinante (rFVIIa) ha sido objeto de varias publicaciones en los